Navigation Links
Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
Date:7/29/2010

f bladder control. Few people with schizophrenia regain normal psychosocial function. The medical need in this disease area is enormous.

ABOUT ITI-007

ITI-007 is a unique, orally available, investigational drug being developed for the treatment of schizophrenia and other neuropsychiatric diseases such as bipolar disorder, major depressive disorder, sleep maintenance insomnia, and for insomnia associated with psychiatric and neurological disorders, such as depression, post-traumatic stress disorder, traumatic brain injury, Parkinson's disease, Alzheimer's disease and mild cognitive impairment.

ITI-007 has a novel combination of pharmacological properties revealed by CNSProfile™ technology that will define the next generation of antipsychotic drugs. ITI-007 combines potent 5-HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine receptors. As a dopamine receptor phosphoprotein modulator (DPPM), ITI-007 has dual properties, acting as a post-synaptic antagonist and as a pre-synaptic partial agonist at D2 receptors with mesolimbic/mesocortical selectivity. ITI-007 also stimulates phosphorylation of glutamatergic NMDA NR2B receptors, in a mesolimbic specific manner downstream of D1 receptor intracellular signaling.  This regional selectivity in brain areas thought to mediate the efficacy of antipsychotic drugs together with a broad serotonergic, glutamatergic, and dopaminergic approach is expected to result in superior antipsychotic efficacy for positive, negative and cognitive symptoms associated with schizophrenia.  Also unusual among antipsychotic drugs is ITI-007's serotonin reuptake inhibition at clinically relevant doses providing antidepressant efficacy as well as antipsychotic efficacy. The unique combination of ITI-007's high-potency blockade of 5-HT2A receptors and DPPM activity should allo
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
3. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
6. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
7. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
8. Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
9. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
10. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
11. Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, announced the Company will ... Tuesday, April 28, 2015 to discuss the 1st quarter ... listen to the call by dialing 1-888-346-3479. International participants ... should ask to be joined into the IGI Laboratories, ...
(Date:4/24/2015)...  Span-America Medical Systems, Inc. (NASDAQ:  SPAN) announced ... second quarter results on Thursday, April 30, after the ... will conduct a conference call at 10:00 a.m. ... financial and operating results for the second quarter ended ... conference call will be available online at ...
(Date:4/24/2015)... -- Introduction of new "Elements" ... for radiosurgery/SBRT   The "Elements" strategy ... the workflow for difficult to treat indications in ... comes full circle with the introduction of automated ... enable on-the-fly generation of consistent treatment plans for ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2
... Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its ... will be issued on Friday, November 5th at 6:30 ... 8:30 a.m. Friday, November 5th - 8:30 a.m. E.D.T.If ... callers use:502-719-4466Password - DUSAA replay of the call will ...
... BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial -- CARMIEL, Israel, Nov. 2, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 2Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 3Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 4Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 5Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 6Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 7Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 8Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 9Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 10
(Date:4/26/2015)... The grand celebration got off to a festive start with ... Deb then introduced Sandy Valentine, the wife of CCAR’s Executive ... his Walk for Recovery on the Appalachian Trail. ... gratitude to the volunteers via video. Board President Tom Kirk ... CCAR’s mission. Volunteer Manager Conrad Sienkiewicz read the names ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 In observance ... will join The Million Nets Pledge, a two-year pledge ... to protect refugee families with one million bednets by ... increased work with UN partners to protect children, refugees, ... malaria. , “There has been a large surge ...
(Date:4/25/2015)... NY (PRWEB) April 25, 2015 By definition, ... and data for the enterprise relying on their judgement and ... smoothly. But according to an article published in ... many times actually be doing a disservice to their responsibilities ... are dotted and t’s are crossed when it comes to ...
(Date:4/25/2015)... York New York (PRWEB) April 25, 2015 ... that Dr. Jerry Blaivas has been chosen by the New ... for his contributions to medicine in the field of Urology. ... the best in his speciality, Genito-Urinary diseases. He was ... specifically in the field of urology. Not only did ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Constellations Recovery ... residence in Westchester County. Just 35 miles from New ... individuals back into everyday life while recovering from addiction. ... 7, 2015, will allow therapists, doctors and treatment centers ... learn more about the opportunities offered by Constellations Recovery., ...
Breaking Medicine News(10 mins):Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3
... number of cardiac patients by 2020 if Indians do not ... above warning has been issued by leading Cardiologists in the ... number of diabetic patients are contributing to the increasing incidence ... suffers from heart diseases. ,'Since heart disease is ...
... a penis enlargement procedure. Too much hype and hoopla ... the internet and spam mails, // has ... to the researchers, it is still under weather down ... with the outcome. ,Nim Christopher, a urologist ...
... due to the new Medicare drug plan. Each plan has its ... These plans require the patients to obtain prior authorization from the ... prior authorization for different drugs. Most states have at least 40 ... make the system complicated and delay the access of the medication. ...
... Health Organisation) today projected that by 2020 road accidents ... outranking public health issues like tuberculosis, diarrhoea and HIV/AIDS.// ... are expected to increase from 135,000 in 2000 to ... from road crashes, according to a WHO report 'World ...
... in the latest edition of the British Dental Journal says ... the knowledge of the early signs and symptoms of the ... at University College, London and Guy's, King's and St Thomas' ... heard of oral cancer or mouth cancer as compared to ...
... a wake up call to obese baby boomers, who could be ... ,Dr. Beth Abramson, foundation spokesperson and cardiologist told CTV."It was ... have soared by nearly 60 per cent and a staggering 52 ... the group between 45 and 60, are not as fit as ...
Cached Medicine News:Health News:Change In Lifestyle Recommended To Avoid Cardiac Disease 2Health News:Medicare Drug Plans Are Onerous and Restrictive 2Health News:Road accidents greater threat than AIDS, TB: WHO 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: